Whether preventing upstream interleukin-6 secretion by cancer-associated fibroblasts (CAFs) could halt the progression of DCIS lesions to invasive cancer in high-risk DCIS breast cancer patients, such as those with low stromal Cav-1 expression, remains to be elucidated and could have significant clinical impact. This evidence concerns the gene IL6 and breast cancer.